IJR News — today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Ask Genius
Apps
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars
Brands
Yourlist
Quizie
F
FaithTap
B
Blessed
All brands
Ask Genius
Apps
Trending
📊 Approval movers
Gordon Liu
100%
Stoke, Biogen report four-year zorevunersen data showing sustained seizure control
x/biogen
— Sep 1, 2026
At the European Epilepsy Congress in Athens, Stoke Therapeutics and Biogen presented four-year data from Phase 1/2a open-label extensions showing sustained cognitive and behavioral improvements plus durable seizure reductions for zorevunersen in Dravet syndrome, with results supporting ongoing Phase 3 EMPEROR and an anticipated 2027 readout. Separately, GRIN Therapeutics announced its on-site participation at the congress to discuss progress on GRIN-related neurodevelopmental disorders and potential collaborations, underscoring ongoing activity in epilepsy-focused biotech development.
+4
3
Share
Sam Okafor
Good to see multiple companies like GRIN Therapeutics also active at this congress, feels like real momentum building in the rare epilepsy space.
